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Off-Pump Coronary Artery Bypass Grafting: 30 Years of Debate
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David Glineur, MD; Juan Grau, MD; Guo-Wei He, MD; Carlo Patrono, MD; John D. Puskas, MD; Marc Ruel, MD, MPH; Thomas A.
Schwann, MD; Derrick Y. Tam, MD; James Tatoulis, MD; Robert Tranbaugh, MD; Michael Vallely, MD; Marco A. Zenati, MD;
Michael Mack, MD; David P. Taggart, MD; Arterial Grafting International Consortium (ATLANTIC) Alliance
O ff-pump coronary artery bypass surgery (OPCAB) hasbeen performed for >30 years.
The promotion of OPCAB was based on its potential
beneﬁts over some of the limitations of traditional on-pump
coronary artery bypass surgery (ONCAB) by avoiding the
trauma of cardiopulmonary bypass (CPB) and by minimizing
aortic manipulation. As such, reductions in early mortality
and perioperative neurological events, renal failure, blood
product transfusions, and hospital length of stay were
expected according to the OPCAB proponents. In contrast,
critics of OPCAB remain concerned about incomplete and/or
poorer quality coronary revascularization with a potential
increase in the need for repeat revascularization and late
mortality.
Despite 3 decades of debate, 115 randomized trials, and
>60 meta-analyses comparing on- and off-pump coronary
artery bypass grafting (CABG), controversy on both the role of
and indications for OPCAB remains vigorous.
In this review, we provide a comprehensive update of the
evidence for the differences in the biological effects of off-
and on-pump surgery and the comparison of the clinical and
angiographic results of the 2 techniques. Furthermore, we
critically address the relevant technical aspects of OPCAB, the
importance of surgeon experience, and the difference in the
costs for the 2 procedures.
Search Strategy
The Arterial Grafting International Consortium (ATLANTIC)
Alliance is an international writing group on coronary
surgery. In January 2018, a comprehensive search to
identify studies that evaluated the biological, clinical,
angiographic, and economic aspects of OPCAB was per-
formed in the following databases from inception to
present: Ovid Medline, Ovid Embase, and the Cochrane
Library (Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials [CENTRAL],
Cochrane Methodology Register). Search keywords included
myocardial revascularization in combination with coronary
artery bypass, on pump, off pump, and OPCAB. Relevant
abstracts were reviewed, and the related articles function
was used for all included studies. References for all
selected studies were cross-checked. The writing group
selected the most relevant papers according to both
methodological and clinical considerations. Observational
series were considered only in the absence of data from
randomized controlled trials (RCTs).
The Technical Evolution of Beating-Heart
Coronary Artery Bypass Surgery
The very ﬁrst direct coronary revascularization procedures in
the early 1960s were performed on the beating heart
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without CPB.1 However, the technique was soon abandoned
because of developments in extracorporeal circulation and
improvement in myocardial protection that made the surgery
safer, standardized, and reproducible. In the early 1980s, 2
South American surgeons, Buffolo2 and Benetti,3 published
their extensive series of OPCAB. Most patients received grafts
to the left anterior descending coronary artery (LAD) and the
main right coronary artery, but with more limited and difﬁcult
grafting of coronary arteries on the posterior and lateral wall.
In the mid 1990s, a minimally invasive left internal mammary
artery (LIMA)–LAD performed through a small left anterior
thoracotomy on the beating heart4 was proposed in combi-
nation with percutaneous coronary intervention (PCI) for the
non-LAD targets.5
Innovative technology played a key role in the develop-
ment of OPCAB by minimizing the motion of the heart during
construction of the anastomosis. Initially, stabilization of the
target coronary vessel was obtained by stay sutures, but the
advent of mechanical stabilizers, by means of pressure or
suction pods, transformed the way OPCAB was performed,
accompanied by an evident improvement in surgical results.6
The critical challenge was the exposure of the lateral and
inferior walls. Initially, lifting of the heart and exposure of the
targets were achieved with multiple slings7 or pericardial
stitches, as proposed by Lima and Salerno.8 The commer-
cialization of pressure- and vacuum-assisted positioners
further changed the ﬁeld and allowed minimization of
hemodynamic changes during exposure. The use of intra-
coronary shunts rather than snaring of the target native
coronary vessel has been shown to signiﬁcantly reduce
intraoperative myocardial dysfunction and hemodynamic
instability during OPCAB.9
The use of a transit-time ﬂowmeter, high-resolution
epicardial ultrasound, or intraoperative ﬂuorescence imaging
allowed intraoperative control of the quality of the anasto-
mosis, an issue of particular relevance during the technically
more complex OPCAB procedure.10
For the future of OPCAB, technology will play an increas-
ingly important role with the adoption of hybrid revascular-
ization and robotic assisted OPCAB. The concept of hybrid
coronary revascularization (HCR) stems from the hypothesis
that the LIMA-LAD graft is superior to coronary stenting of the
LAD, whereas contemporary drug-eluting stent–PCI is nonin-
ferior to venous bypass grafts used for non-LAD tar-
gets. Although still limited to sporadic experiences in
dedicated centers, HCR has the potential to combine the
advantages of minimally invasive OPCAB with complete
coronary revascularization.
The use of robotic assistance during CABG has been
associated with superior cosmetic results and reduced
postoperative pain but also longer operative times and higher
costs.11
Differences in Systemic Inﬂammatory
Reaction and Platelet/Coagulation Activation
After On- and Off-Pump CABG
CABG elicits a complex prothrombotic and proinﬂammatory
response that peaks within a time frame spanning from the
end of CPB to the early hours thereafter. These molecular
changes may persist for days or weeks after CABG.12 In
particular, several studies have described marked and
protracted activation of several molecular pathways, reﬂect-
ing a systemic inﬂammatory reaction, platelet and coagulation
activation, and increased oxidative stress and endothelial
dysfunction.13 Interestingly, these changes appear to occur
after both ONCAB and OPCAB, with a relatively limited
number of these pathways (eg, oxidant stress) showing more
pronounced activation in the presence of CPB.13
Systemic Inﬂammatory Reaction
Patients undergoing CABG constitute a distinct high-risk
group characterized by advanced atherosclerotic disease, low-
grade systemic inﬂammation, and the clustering of several
other comorbidities.13 The CABG operation per se is a potent
triggering factor for cardiovascular events because it elicits
major endocrine stress and systemic inﬂammatory response,
which involves the release of acute-phase proteins and sepsis-
like symptoms during postoperative recovery.14,15 The inﬂam-
matory response during CABG may be related, at least in part,
to the use of CPB that induces leukocyte and platelet
activation, thrombin and plasmin-mediated procoagulant and
ﬁbrinolytic effects, and a rapid and sustained multifold
increase in the circulating levels of proinﬂammatory
mediators.16 Myocardial tissue ischemia as a result of aortic
cross-clamp, reperfusion injury, plaque rupture and microem-
bolization, and other factors (eg, type of anesthesia) also may
play a role in CABG-related inﬂammation.17
If and to what extent avoidance of CPB can reduce or even
eliminate the systemic inﬂammatory reaction after surgery is
controversial. Studies that evaluated the circulating levels of
proinﬂammatory cytokines (IL-6, -8, and -10) after off- and on-
pump- surgery reported contradictory results.14,18–22
The concomitant use of cardiotomy suction or non–
heparin-bounded CPB circuits in some of the trials is a
plausible cause of heterogeneity and may partially explain the
contradictory results.
Interestingly, the severity of the inﬂammatory response to
OPCAB might be affected by the type of anesthesia.23
Inﬂammation has been proposed to have an important role in
determining early postoperative complications (eg, low-output
syndrome, myocardial injury, and atrial ﬁbrillation or stroke).
Indeed, increased preoperative CRP (C-reactive protein) levels
are independently associated with early and late mortality in
CABG patients.24 In other studies, preoperative levels of IL-6,
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IL-8, and MCP-1 (monocyte chemoattractant protein 1)
predict postoperative atrial ﬁbrillation development in CABG
patients.25 Gaudino et al26 described a signiﬁcant correlation
between a single-base promoter mutation of the polymor-
phism of the IL6 gene, the postoperative level of IL-6, and the
development of pulmonary and renal complications and atrial
ﬁbrillation after CABG. In RCTs, OPCAB has been associated
with signiﬁcantly lower myocardial injury and increase in
inﬂammatory mediators compared with ONCAB,14,15 although
early mortality rates did not differ signiﬁcantly.27 Neverthe-
less, it must be noted that the results of pharmacological
treatment aimed at reducing the postoperative inﬂammatory
reaction after CABG (corticosteroids, statins) have been
mixed,28,29 so the role of attempts to modulate inﬂammation
in determining postoperative clinical outcome after CABG
remains to be determined.
Platelet and Coagulation Activation
Activation of the plasmatic and cellular components of the
hemostatic system occurs through 2 distinct mechanisms,
namely, contact of blood with the surgical wound and contact
of blood with the foreign surface of the CPB circuit.30 The
former plays a major role in the early activation of the
hemostatic system that results in thrombin generation.
Besides catalyzing the conversion of ﬁbrinogen to ﬁbrin,
thrombin has multiple cellular targets (both in blood [eg,
platelets] and the vessel wall) through the interaction with
protease-activated receptors.30,31 Moreover, there is bidirec-
tional interplay between blood coagulation and inﬂammation,
with activation of the former leading to an inﬂammatory
reaction and vice versa.30 Circulating platelets are activated
during CABG by several distinct mechanisms, including
thrombin interacting with platelet PAR-1 (protease-activated
receptor 1), interaction with ﬁbrinogen bound to the CPB
circuit, and contact with foreign surfaces. These activation
processes eventually lead to reduced numbers of circulating
platelets and perioperative platelet dysfunction.30 Moreover,
activated platelets release a broad range of inﬂammatory
mediators, thereby reinforcing the inﬂammatory reaction.31
The increased vascular biosynthesis of the antithrombotic
prostanoid prostacyclin (PGI2) represents a homeostatic
response to inﬂammation and platelet activation.32
A limited number of studies have compared the effects of
ONCAB versus OPCAB on platelet activation and aggregation
and failed to demonstrate major differences between
them.30,33–35 It should be emphasized that these studies
relied on measurements of platelet function ex vivo, which do
not necessarily reﬂect the extent of platelet activation
in vivo.31
A different and more clinically relevant way of assessing
the potential hemostatic/prothrombotic differences related to
ONCAB versus OPCAB is represented by studies of the
pharmacodynamic response to antiplatelet drugs in these
settings.32,33 In a study by Zimmermann et al,33 the
antiplatelet effect of aspirin (100 mg/day started on day 1
after surgery) evaluated at day 5 was largely impaired after
CPB but not after CABG without CPB; therefore, increased
platelet turnover after CPB appears to contribute to transient
aspirin “resistance” because an increased number of new
platelets might be competent to form Thromboxane A2 (TXA2)
within the 24-hour dosing interval.33 Consistent with this
hypothesis, Cavalca et al recently reported impaired aspirin
pharmacodynamics early after ONCAB that were associated
with signiﬁcant increases in immature platelets, total
platelets, platelet mass, thrombopoieitin, IL-6, glycocalicin,
leukocytes, and high-sensitivity CRP.32 IL-6 can control
inﬂammation through CRP and modulate megakaryocyte
fragmentation, differentiation, and platelet release directly
or through thrombopoieitin.32 Changes in thrombopoietic
indexes were largely reversible 3 months after surgery.32 As
shown by 3 independent studies, shortening the dosing
interval (ie, twice-daily dosing), but not doubling the dose,
safely rescued the impaired antiplatelet effect of low-dose
aspirin and prevented platelet activation associated with
acute inﬂammation and enhanced platelet turnover following
cardiac surgery.32,36,37
To summarize, at present there is no clear-cut demonstra-
tion of a substantial reduction of the postoperative systemic
inﬂammatory reaction and platelet activation after OPCAB. The
antiplatelet effect of low-dose aspirin is transiently impaired
following ONCAB because of enhanced platelet turnover.
Comparison of Short-Term Clinical Outcomes
of On- and Off-Pump CABG
The beneﬁts and risks of OPCAB have been the subject of
several large RCTs, observational studies and registries, and
>60 meta-analyses. In the largest randomized comparisons
(CORONARY [CABG Off or On Pump Revascularization] and
ROOBY [Randomized On/Off Bypass] trials), there were no
differences in the primary study end point at 30 days.27,38 In
CORONARY,27 the primary composite outcome of death,
nonfatal stroke, or nonfatal myocardial infarction (MI) was
similar between OPCAB and ONCAB (9.8% versus 10.3%,
P=0.59). Similarly in ROOBY, the primary composite outcome
of 30-day death or major complications was similar between
the 2 arms (7.0% versus 5.6%, P=0.19).38 Furthermore, there
was no difference in any individual component of these early
composite outcomes (Table 1). Consistent with the purported
beneﬁts of off-pump surgery, several other perioperative
complications (transfusion, reoperation for bleeding, acute
kidney injury, and respiratory complications) were reduced in
the off-pump patients in CORONARY.
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In GOPCABE (German Off-Pump CABG in Elderly Trial), a
German RCT including only patients aged >75 years, there was
no signiﬁcant difference in the primary composite end point of
death, stroke, MI, or new renal replacement therapy (7.8%
versus 8.2%, P=0.74) at 30 days41 and no differences in the
individual components of the composite end point (Table 1).
However, there was an increased number of repeat revascu-
larizations with OPCAB (1.3% versus 0.4%, P=0.04), a ﬁnding
also observed in CORONARY (0.7% versus 0.2%, P=0.01).
Of note, no reduction in stroke was noted both in hospital
and at 1 year (CORONARY: 1.5% versus 1.7%; [hazard ratio
(HR): 0.90; 95% conﬁdence interval (CI), 0.57–1.41]; GOP-
CABE: 3.5% versus 4.4%; P=0.26).41,42
At 12 months, the primary composite end point was not
different in the OPCAB and ONCAB patients in GOPCABE
(13.1% versus 14.0%; P=0.48) or in CORONARY (12.1% versus
13.3%; P=0.24). In ROOBY, the primary outcome favored on-
pump surgery (9.9% versus 7.4%; P=0.04), as did death from
cardiac causes (2.7% versus 1.3%; P=0.03).
In contrast to the randomized trials, large propensity-
matched databases have reported superior short-term out-
comes with OPCAB, particularly in higher risk patients.
Polomsky and associates, using data from the Society of
Thoracic Surgeons Adult Cardiac Surgery Database (STS ACSD)
on 876 081 elective isolated CABG operations, found that the
odds ratios (ORs) for death and most major complications were
signiﬁcantly lower with OPCAB than with ONCAB.43
A meta-analysis of 35 propensity-matched studies and
123 137 patients found OPCAB to be superior to on-pump
surgery for all short-term outcomes including mortality.44
To summarize, RCTs have reported similar operative risk for
off- and on-pump CABG, whereas single-center studies have
reported better outcomes, particularly in high-risk patients.
Comparison of Long-Term Clinical Outcomes
of On- and Off-Pump CABG
Conﬂicting evidence exists on whether off-pump CABG is
associated with inferior long-term outcomes. At 5 years, there
was no difference in the primary outcome in the CORONARY
trial.39 In the ROOBY trial, however, 5-year survival was
signiﬁcantly worse in the off-pump group (15.2% versus 11.9%;
P=0.02).40 Event-free survival was also signiﬁcantly decreased
in the off-pump group (31.0% versus 27.1%; P=0.05), along
with MI and the need for repeat revascularization (Table 1).
In a single-center observational study of 12 812 patients
from Emory University, Atlanta, GA, USA, there was no
difference in 10-year mortality between on- and off-pump
surgery after propensity score covariate adjustment (HR:
1.00; 95% CI, 0.88–1.14).45 Importantly, the authors reported
that the key to long-term survival was completeness of
revascularization in both on- and off-pump patients. Similarly,
in 942 propensity score–matched patient pairs from a single
Italian center, there was no difference in 10-year mortality
between on- and off-pump surgery (HR: 1.3; 95% CI, 0.91–
1.9).46 In a study from the United Kingdom of >13 000
propensity-matched patients followed for 13 years, there was
no difference in survival, suggesting that when OPCAB is
performed by highly experienced surgeons, there is no
adverse effect on survival.47
In contrast, a propensity-matched single-institution study
from Baylor Research Institute, Dallas, TX, USA showed an
elevated risk of late mortality at 10 years with OPCAB (HR:
1.18; 95% CI, 1.02–1.38).48 These concerns about late
mortality were further explored in a meta-analysis of 42 RCTs
and 31 risk-adjusted observational studies that included
1.2 million patients.49 OPCAB was associated with a statis-
tically signiﬁcant 10% relative increase in the probability of
mortality at 5 years (95% CI, 5.0–15.0%) that increased to
14% at 10 years in the observational studies (95% CI, 11.0–
17.0%). It is important to note, however, that although
statistical signiﬁcance was reached, the clinical relevance of
the reported difference remains to be determined (absolute
difference: 0.5% at 5 years and 3% at 10 years).
The most recent meta-analysis including only RCTs with
≥4-year outcome and pooling data from 8145 participants
reported an OR for long-term mortality of 1.16 for OPCAB
(95% CI, 1.02–1.32).50
To conclude, long-term data are discordant. Based on the
current evidence, the possibility that off-pump surgery results
in worse clinical outcomes cannot be excluded.
OPCAB in Speciﬁc Subsets of Patients
High-Risk Populations
Multiple studies have suggested a beneﬁt of OPCAB in high-
risk patient populations. A recent meta-analysis of RCTs
demonstrated a signiﬁcant relationship between the patient
risk proﬁle and the beneﬁts from OPCAB, with the most
beneﬁt derived from reduced perioperative morbidity.51
An analysis of the STS ACSD from 1997 to 2007 showed
that there were 38% and 55% reductions in the odds of early
mortality for patients undergoing off-pump operations in the
third- and fourth-highest risk quartiles, respectively.52 In
contrast, a study of the Australian and New Zealand Society of
Cardiac and Thoracic Surgeons database for high-risk patients
associated OPCAB with reduced morbidity but showed similar
operative mortality as compared to ONCAB.53
Impaired Ventricular Function
As for patients with low ejection fraction (EF), an analysis of
the STS ACSD from 2008 to 2011 of 25 667 patients with low
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EF (<30%) found that the risks of death, stroke, and major
adverse cardiac events (MACE) were lower in the OPCAB
group.54 These ﬁndings were corroborated by analysis of the
Japan Adult Cardiovascular Surgery Database in which
OPCAB was associated with reduced early morbidity and
mortality in patients with EF <30%.55 A meta-analysis of
observational studies concluded that OPCAB may be
associated with lower incidence of early mortality in patients
with impaired left ventricular function but noted that the
method of handling the conversion-related mortality in
each study was uncertain and may have inﬂuenced the
results. In addition, incomplete revascularization (IR) in the
OPCAB group occurred more often and may explain why
the early advantage in mortality was not maintained long
term.56
Advanced Age
Advanced age is a known risk factor in CABG.57 In a
systematic review of 16 observational studies of CABG in
octogenarians (18 685 ONCAB and 8938 OPCAB), in-hospital
mortality (pooled OR: 0.64; 95% CI, 0.44–0.93; P=0.02), and
stroke (pooled OR: 0.61; 95% CI, 0.48–0.76; P<0.001) were
signiﬁcantly lower in OPCAB.58 However, results from a
Danish registry did not show a difference in outcomes
between ONCAB and OPCAB in patients aged >70 years.59 A
propensity matched study of 6943 pairs of octogenarians
showed a 30% reduction in the odds of stroke with OPCAB
using the Nationwide Inpatient Sample (NIS).60 In addition,
the largest RCT to date comparing OPCAB and ONCAB in
elderly patients (aged ≥75 years), reported no signiﬁcant
difference between ONCAB and OPCAB with regard to the
composite outcome of death, stroke, MI, repeat revascular-
ization, or new renal replacement therapy within 30 days and
1 year after surgery.41
Female Sex
Numerous studies report CABG mortality to be higher in
women.61,62 In fact, according to the STS CABG risk model,
female sex is associated with increased risk of operative
mortality (OR: 1.31), major complications (OR: 1.18), and
increased hospital length of stay (OR: 1.24).57 OPCAB,
however, may narrow or eliminate this disparity in outcomes
between women and men. A large study at an experienced
OPCAB US academic center concluded that OPCAB dispro-
portionately beneﬁts women and narrows the sex disparity in
outcomes after CABG. Female patients (n=3248) and those
treated with OPCAB (n=4492) were older and had more
comorbidities than male patients (n=8165) and those treated
with ONCAB (n=6921), respectively. Women treated with
ONCAB had risk-adjusted ORs of 1.60 for death (P=0.01) and
1.71 for MACE (P<0.001) compared with men who had
ONCAB. In contrast, women treated with OPCAB had
outcomes similar to men who had either OPCAB or ONCAB.
Among women, OPCAB was associated with a signiﬁcant
reduction in death (OR: 0.39; P=0.001) and MACE (OR: 0.43;
P<0.001).63
These ﬁndings were replicated at a national level in an
STS ACSD study of 63 experienced centers that performed
>100 OPCAB cases between 2004 and 2005. Women
(n=11 785) and those treated with OPCAB (n=16 245) were
older and had more comorbidities than men (n=30 662) and
those treated with conventional ONCAB (n=26 202), respec-
tively. The risk-adjusted ORs for death and major compli-
cations were signiﬁcantly lower with OPCAB than with
ONCAB. Among ONCAB cases only, women had a signiﬁ-
cantly greater adjusted risk of death, prolonged ventilation,
and longer hospital length of stay than men; however,
among OPCAB cases, women had similar outcomes.64 A
meta-analysis of observational studies associated OPCAB
with reduced perioperative MI but not with reduction of
other morbidities or operative mortality.65 Of note, women
undergoing OPCAB received fewer grafts than those under-
going ONCAB.
OPCAB may have a selective beneﬁt for women. The
underlying mechanism is unclear and is unlikely to be related
to avoidance of CPB because there is no major sex difference
in outcomes associated with valve surgery.66 It is interesting,
however, that women who undergo OPCAB are more likely to
receive an internal mammary artery bypass than those
undergoing ONCAB.67
Neurological Risk
The possible association of OPCAB with reduced stroke with
enhanced beneﬁt in higher risk patients67 argues for a
potential beneﬁt in patients with a history of atheromatous
aorta or cerebrovascular disease. A large single-center study
utilizing propensity-matched analysis in patients with athero-
matous disease of the ascending aorta associated ONCAB
with an increased risk of postoperative stroke (OR: 1.4;
P=0.05) and operative mortality.68 Another study associated
OPCAB with reduced stroke and operative mortality in a
similar population.69 Patients with carotid stenosis may have
a potential beneﬁt with OPCAB,70 but the evidence is
inconclusive, and when it comes to combined CABG and
carotid endarterectomy, again, the data are sparse, but both
OPCAB and ONCAB may provide equivalent outcomes.71 In
patients with a history of preoperative cerebrovascular
events, OPCAB does not appear to confer a risk beneﬁt with
regard to postoperative neurological outcome compared with
ONCAB.72 Of note, postoperative cognitive impairment is
similar after on- and off-pump CABG.73
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End Organ Failure
The data on the beneﬁt of OPCAB in patients with end-organ
failure, including renal failure and cirrhosis, are limited to
observational studies and mostly small patient numbers.
Despite a higher rate of IR, a propensity-matched analysis
associated on-pump with increased operative mortality in
patients with advanced chronic kidney disease.74 A meta-
analysis including 17 studies with 201 889 patients with
chronic kidney disease associated OPCAB with lower early
mortality (OR: 0.88; 95% CI, 0.82–0.93; P<0.0001) and
morbidity compared with ONCAB. However, there was no
difference regarding long-term survival (HR: 1.08; 95% CI,
0.86–1.36; P=0.51).75 A large study based on the National
Health Research Institute of Taiwan reported similar out-
comes of OPCAB and ONCAB in patients on dialysis.76 Similar
ﬁndings were reported by a meta-analysis of 10 retrospective
studies.77
Cirrhosis substantially increases the operative risk in
patients who undergo cardiac surgery. In a national sample
of 3 046 709 patients who underwent CABG procedures, of
which 744 636 (24.4%) were OPCAB, 6448 patients (0.3%)
had cirrhosis. In the overall CABG group, cirrhosis was
independently associated with increased mortality (adjusted
OR: 6.9; 95% CI, 2.8–17) and morbidity (adjusted OR: 1.6; 95%
CI, 1.3–2.0), The OPCAB subgroup analysis revealed that the
presence of cirrhosis did not affect mortality or morbidity
unless there was severe liver dysfunction. In the ONCAB
patients, however, cirrhosis was associated with increased
mortality and morbidity regardless of the severity of liver
dysfunction.78
In summary, the available evidence suggests that OPCAB
can be associated with better outcomes in high-risk patents.
Elderly patients, patients with low EF, those with high
neurological risk, women, and patients with end-organ failure
may beneﬁt from off-pump surgery, although the extent of this
beneﬁt remains unclear at present.
OPCAB and Graft Patency
The effect of OPCAB on graft patency rate is still controver-
sial. In the angiographic analysis of the ROOBY trial, the 1-
year patency rate in the off-pump arm was signiﬁcantly lower
than in the on-pump arm. Follow-up angiography was obtained
in 62% of the patients of the initial cohort. Overall patency
rate was 82.6% in the off-pump group and 87.8% in the on-
pump group (P<0.001). At least 1 occluded graft was found in
36.5% of off-pump versus 28.7% of on-pump patients (relative
risk: 1.27; 95% CI, 1.09–1.48). Arterial conduits (mainly LIMA
to LAD grafts) showed similar patency rates in the 2 groups
(92.9% versus 94.8%; P=0.13), whereas saphenous vein grafts
had a signiﬁcantly lower patency rate in the off-pump group
(76.6% versus 83.8%; P<0.001). Interestingly, however, both
arterial and venous conduits had signiﬁcantly lower perfect
patency in the OPCAB group. Grafts to the posterior
descending artery had the worse patency when performed
off-pump (74.1% versus 82.8%; P=0.003).79
A smaller single-institution and single-surgeon RCT
reported similar angiographic outcomes with the 2
techniques.80 A Japanese RCT including 167 consecutive
patients found no difference in patency but a numerically
higher perfect patency rate in the on-pump group (96% versus
93%; P=0.09), particularly for grafts to the right coronary
system (99% versus 90%; P=0.02).81 A post hoc analysis of
the large angiographic database of the PREVENT (The Project
of Ex-vivo Vein Graft Engineering via Transfection) IV study
(1920 patients and 4736 grafts) found no difference in the
patency rates of the 2 techniques.82
All the meta-analyses report a higher incidence of graft
occlusion or failure in the OPCAB arm. A meta-analysis of 12
RCTs pooling together angiographic data from 3894 (OPCAB)
and 4137 (ONCAB) grafts reported an increased risk of
occlusion of all grafts in the OPCAB group (relative risk: 1.35;
95% CI, 1.16–1.57), mainly due to saphenous vein graft failure
(relative risk: 1.41; 95% CI, 1.24–1.60).83 Interestingly, there
was no signiﬁcant difference in graft occlusion between the 2
techniques for internal mammary artery and radial artery grafts.
The most recent meta-analysis pooled angiographic data
on 7011 grafts and found an OR of 1.51 for occlusion in the
OPCAB arm (95% CI, 1.21–1.88; P=0.002).84 Differences in
surgeons’ experience, varying completeness of follow-up, and
angiographic deﬁnitions are the plausible reasons for the
reported discrepancies. In particular, the use of overall
patency in some series and perfect patency (ie patency
without any irregularity) in others makes the comparison of
the different studies difﬁcult.
To summarize, OPCAB seems associated with lower
patency and perfect patency rate, although contradictory
results have been reported.
Completeness of Revascularization
Completeness of myocardial revascularization is a corner-
stone of CABG. In a meta-analysis including aggregated data
from 30 389 patients, complete myocardial revascularization
had a strong protective effect against long-term mortality (HR:
0.63; 95% CI, 0.53–0.75).85
In most published comparative series, the number of grafts
per patient in the OPCAB arm is lower than in the pump-
assisted group.86 A relation with surgeon experience seems to
exist, and this has led to concerns that off-pump surgery is
achieved at the expense of the completeness of the
revascularization, especially when performed by less experi-
enced surgeons.
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In fact, despite technological advances, grafting the inferior
and posterolateral wall off-pump can be challenging. In the
ROOBY trial, the numbers of planned grafts per patient were
similar in both groups (3.0 versus 3.0; P=0.98), but the
number of grafts performed was inferior in the OPCAB arm
(2.9 versus 3.0; P<0.001).40 In the on-pump group, 11.1% of
patients received fewer grafts than planned compared with
17.8% in the OPCAB series (P<0.001); at 5 years, the
respective rates of repeat CABG were 0.5% and 1.4%
(P=0.02). In the CORONARY trial,87 however, which involved
more expert off-pump surgeons, the rate of IR was similar in
the 2 groups (11.2% OPCAB versus 10% ONCAB; P=0.05).
Notably, in CORONARY, no differences in repeat revascular-
ization by PCI or CABG were found at 5 years (2.8% versus
2.3% [P=0.29] and 0.4% versus 0.2% [P=0.17]).
IR in the OPCAB group has been correlated with long-term
mortality. In a large study in which 5423 on-pump patients
were propensity matched with 5423 OPCAB patients, the
latter had higher prevalence of IR (6.9% ONCAB versus 13.6%
OPCAB; P<0.001). Long-term mortality was signiﬁcantly
higher for patients undergoing incomplete OPCAB.88
In a recent analysis of >13 000 patients from a single
institution, a detrimental effect of IR on survival was demon-
strated when at least 1 territory was not revascularized in
OPCAB patients. Interestingly, a similar effect was evident only
when 2 coronary territories were left ungrafted in the on-pump
series; this ﬁnding suggests that the pathogenesis and clinical
consequences of IR may differ between the 2 techniques.89
It must be noted, however, that the interpretation of the
literature on the subject is problematic for several reasons.
The deﬁnition of IR varies markedly among studies, making
comparisons between trials very difﬁcult. In addition, IR can
be a surrogate marker of a greater burden and complexity of
coronary disease and a worse risk proﬁle for the patient. In
fact, variables such as reduced EF, advanced age, heart
failure, and reoperation have been associated with both IR
and survival.90 In these situations, it is difﬁcult to determine
the effect of IR per se and the role of various preoperative risk
factors that are prevalent in the same patients.
In summary, IR is probably an explanation for the worse
long-term outcomes of OPCAB and seems to be related to
surgeon’s experience.
The Role of Surgeon Experience
The individual surgeon’s expertise in OPCAB and hospital
volume have long been considered important determinants of
outcome.91
RCTs suggesting increased risk with OPCAB have been
criticized by those who believe that surgeon experience plays a
major role in determining outcomes. In the ROOBY trial, in
which OPCAB was associated with increased 5-year mortality
(15.2% in the OPCAB group versus 11.9% in the on-pump group;
P=0.02), the 53 participating surgeons enrolled an average of
only 8 patients per year during the study period and had a high
conversion rate to on-pump surgery (12%) and IR (18%).40
Moreover, in 60% of the cases, a resident was the primary
surgeon. In the GOPCABE study,41 in which surgeons were
required to be established experts with an average of 514
OPCAB procedures (median: 322), no signiﬁcant differences
between OPCAB and on-pump surgery were found. In the
CORONARY trial, each procedure was performed by a surgeon
who had expertise in the speciﬁc type of surgery (>100 cases
using the speciﬁc technique, off-pump or on-pump) and similar
5-year outcomes with OPCAB and ONCAB were reported.27
Among the observational studies, Lapar et al found a
signiﬁcant surgeon volume–outcome relationship for mortality
after OPCAB with a threshold of >50 operations per year.92
Glance and colleagues, however, in a registry study from the
New York State Database including 36 930 patients and 181
surgeons at 33 hospitals, did not ﬁnd any association
between OPCAB surgeon case volumes and mortality.91
In a recent post hoc analysis of the ART trial including 1260
and 1700OPCAB and on-pump patients, respectively,93 OPCAB
performed by “sporadic” OPCAB surgeons (1–5 OPCAB proce-
dures) presented a higher rate of conversion (12.9%) and a
higher rate of operative mortality (4.8%) compared with ONCAB
despite similar distribution of risk factors. OPCAB performed by
3 high-volume OPCAB surgeons (>60) showed a very low
conversion rate (1%) and 5-year mortality comparable to
ONCAB performed by 95 “on-pump only” surgeons. According
to the STS ACSD, 84% of participating centers performed <50
off-pump cases per year, 34% of surgeons performed no off-
pump operations, and 86% of surgeons performed <20 off-
pump cases per year.94 A recent analysis of the US NIS95
showed that OPCAB performed in low-volume centers and by
low-volume surgeons was associated with signiﬁcantly
increased risk-adjusted mortality. In contrast, OPCAB was
associated with lower risk adjusted mortality when performed
in high-volume hospitals (≥164 cases/year) and by high-
volume surgeons (≥48 cases/year).
To summarize, it seems likely that the unique technical
challenges of OPCAB may lead to poorer outcomes during
each surgeon’s “learning curve.” To minimize the learning
curve effect, appropriate patient selection, individualized
grafting strategy, peer-to-peer training of the entire team,
and graded clinical experience are of paramount importance.
Intraoperative Conversion From Off-Pump to
On-Pump
An intraoperative switch from an OPCAB to an ONCAB
approach is described as intraoperative conversion (IOC).96
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IOC has been classiﬁed as elective, in which the change
from OPCAB to ONCAB is aimed at the prevention of
hemodynamic instability and occurs before the start of any
distal coronary anastomosis, and emergent, in which the
conversion takes place following the onset of hemodynamic
instability and typically after the start of the construction of a
distal anastomosis.
The reported rate of IOC is quite broad. In a recent analysis of
the STS ACSD involving over 196 000 patients, the reported
conversion rate was 5.5% of which 50% were elective.97
In a meta-analysis including 18 870 patients, IOC occurred
in 4.9% of the cases.98 In the CORONARY trial, the rate of IOC
was 7.9%,99 ranging from 0% to 60% among hospitals. The
highest rates of IOC were reported before cardiac manipula-
tion (43.5%) and grafting of the LAD (18.3%), whereas IOC
before grafting of the lateral and inferior walls was less
frequent (9.7% and 3.8%, respectively). In 15.1% of the cases,
hemodynamic instability occurring soon after the induction of
anesthesia led surgeons to convert before starting surgery.
The most common reason for IOC is hypotension (32.3%),
followed by either small size (26.9%) or intramuscular course of
target vessels (22.6%), ischemia (17.7%), and arrhythmias
(11.3%); less common reasons were hemorrhage, graft occlu-
sion, calciﬁed aorta, and need for concomitant surgery.96,99
Elective IOC is usually well tolerated and associated with
no increase in operative mortality.96,99,100
In contrast, emergency IOC is associated with signiﬁcantly
increased mortality risk.96 In an analysis based on the STS
ACSD, Keeling et al97 reported observed to expected mortal-
ity of 1.4 for an elective IOC, 1.6 for emergency IOC for
visualization reasons, and 2.7 for emergency IOC for hemo-
dynamic instability. In the previously cited meta-analysis,
emergency conversion raised the OR of mortality to 6.99 (95%
CI, 5.18–9.45).98 In addition to the noted increased mortality,
IOC is also associated with increased risk of almost all
perioperative complications including myocardial ischemic
injury, stroke, renal failure, and prolonged ventilation.97,100,101
Furthermore, IOC is associated with increased costs102 as
well as hospital readmissions and infectious complications.103
Midterm and event-free survival is signiﬁcantly reduced for
patients who undergo IOC.64,104
Identifying patients at high-risk for IOC a priori and
avoiding an ill-fated attempt at OPCAB likely constitutes the
best strategy to improve OPCAB outcomes. Keeling et al97
showed that older age, EF <35%, preoperative need for intra-
aortic balloon pump, increasing number of diseased native
coronary vessels, history of congestive heart failure, and
urgent status of surgery are all independent predictors of IOC.
Other identiﬁed risk factors for IOC are left main coronary
artery disease, intramyocardial course of coronary targets,
reoperative procedures, and increasing number of coronary
grafts constructed.99,100,105
The rate of IOC declines with increasing OPCAB surgeon
and institutional experience.100,101
In summary, IOC occurs in a relatively small percentage of
OPCAB cases, although the incidence is related to surgeon
experience. Elective IOC is usually a benign event, whereas
emergency IOC is associated with signiﬁcantly worse out-
comes.
Comparison of Hospital Costs Between Off-
and On-Pump CABG
Controlling costs in health care continues to be a challenge,
and CABG, as one of the most frequently performed
procedures in the world, remains a visible priority. Indeed,
OPCAB was initially embraced as a promising procedure to
reduce costs associated with CABG.106
Despite extensive research and multiple published studies
during the past 2 decades, there continues to be debate
regarding cost advantages of one versus the other approach.
Table 2 summarize the most important series comparing
the cost of off- and on-pump CABG.
Scott et al,116 in an observational study, found that patients
undergoing ONCAB had signiﬁcantly longer time to extubation,
increased blood use, longer intensive care unit and postoper-
ative lengths of stay, and higher in-hospital mortality than
patients undergoing OPCAB, which would translate into signif-
icantly higher expenses associated with ONCAB. Similarly, in a
large propensity-matched registry,112 total costs were higher
for ONCAB. Speciﬁcally, the operative procedure showed
similar costs (roughly $5000), but other in-hospital costs
including surgical devices, intensive care unit, cardiacward, and
blood products were signiﬁcantly higher in patients undergoing
ONCAB. At 1-year follow-up, this difference persisted ($12 000
for OPCAB versus $14 000 for ONCAB; P<0.001).
In contrast, data from the CORONARY trial showed no
difference in costs between the 2 techniques.115 During the
index hospitalization, the cost for patients undergoing OPCAB
was $8626 compared with $8567 for ONCAB, with a
nonsigniﬁcant difference of $59. At follow-up, this trend of
neutrality continued ($37 more for OPCAB at 6 months and
$28 less for OPCAB at 1 year). A sensitivity analysis was also
performed to evaluate the potential inﬂuence of supplies for
the 2 surgical strategies. When OPCAB supplies cost $1000
less than ONCAB supplies, the cost savings with OPCAB were
roughly $1000. However, increasing the cost of off-pump
supplies to $2000 showed a linear increase in the incremental
cost up to cost saving of $1000 for on-pump surgery.
Alternatively, the ROOBY trial117 reported signiﬁcant cost
saving with ONCAB ($56 023 versus $59 623; P=0.05). This
ﬁnding was also conﬁrmed by a large retrospective study
(63 000 patients)113 in which multivariable regression anal-
ysis showed a higher ﬁnal cost by $1497 per patient in those
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treated by OPCAB (P<0.001). Factors inﬂuencing the ﬁnal
cost of off-pump surgery were age >65 years, number of
grafts, duration of anesthesia, very low EF, and low to medium
hospital OPCAB volume.115,118 Interestingly, no difference in
cost was found in the CORONARY trial118 among the different
geographic areas for ONCAB and OPCAB.115
It must be noted that the cost analyses should be
extrapolated to individual programs with caution because of
the high variability in the cost of devices for different
institutions and countries.
To summarize, no clear evidence shows that OPCAB
signiﬁcantly reduces in-hospital costs.
Anaortic, Total Arterial, Off-Pump CABG
The original thesis of OPCAB was that removing the CPB
from the procedure would reduce pump-related
inﬂammation, end-organ injury, and stroke. The vast major-
ity of these procedures were performed using an in situ
LIMA to the LAD and ≥1 proximal aortocoronary vein grafts
placed onto the ascending aorta using a partial-occlusion
clamp.
Anaortic OPCAB refers to a distinct off-pump technique
with complete avoidance of aortic manipulation. This may
prevent dislodgement and embolization of atheromatous
plaque in the aorta and reduce the risk of stroke.119 In situ
grafts are used including one or both of the internal mammary
arteries (and the gastroepiploic, in some cases) to avoid the
need for proximal aortocoronary anastomoses and the
associated aortic manipulation. Composite grafts are con-
structed as required including “T” or “Y” grafts or tandem or
“I” grafts if an internal mammary artery is extended with a
second conduit. Consequently, this technique also has a high
percentage of total arterial conduits.
Table 2. Overview of the Series Comparing the Cost of OPCAB and ONCAB
First Author Year Study Design
Number of Patients; Cost Beneﬁt
Off-Pump On-Pump
Arom107 1999 Retrospective, hospital costs 62; 21% decreased costs 243
Boyd108 1999 Retrospective, hospital costs 30; 14% decreased costs 60
Ascione109 1999 Prospective, randomized
hospital costs
100; 30% decreased costs 100
Nathoe110(OCTOPUS trial) 2003 Multicenter, prospective,
randomizedhospital and
1-year costs
142; hospital: 14% decreased costs, P<0.01;1
year: 12% decreased cumulative costs (P<0.01)
139
Puskas111 2004 Prospective, randomizedhospital
and 1-year costs
100; hospital: 11% decreased costs (P=0.002)1
year: 8% decreased cumulative costs (P=0.08)
100
Lamy112 2006 Propensity-matched registry 1233; 1-year total costs: 15% decreased (P<0.001) 1233
Chu113 2009 Data from Nationwide
Inpatient Sample 2004
14 389; $1497 (95% CI, $779–$2216) more in
overallhospitalization costs in OPCAB than ONCAB
48 658
Shroyer38(ROOBY trial) 2009 Multicenter prospective,
randomizedhospital costs
1104 1099 Hospital:
6% decreased
costs (P=0.05)
Houlind114(DOORS trial) 2013 Multicenter, prospective,
randomizedhospital and
reintervention costs
450; hospital and reinterventions:
7% decreased costs
450
Lamy115(CORONARY trial) 2014 Multicenter, prospective,
randomizedhospital
and 1-year costs
2375 2377; hospital:
1% decreased
costs (P=ns);
1 year: 1%
decreased
cumulative
costs (P=ns)
Lamy39(CORONARY trial) 2016 Multicenter, prospective,
randomized5-year costs
2375 2377; 5 years:
1% decreased
cumulative
costs (P=ns)
CABG indicates coronary artery bypass grafting; CORONARY, CABG Off- or On-Pump Revascularization; DOORS, Danish On-pump Off-pump Randomization Study; OCTOPUS, A comparison
of on-pump and off-pump coronary bypass surgery in low-risk patients trial; ONCAB, on-pump coronary artery bypass surgery; OPCAB, off-pump coronary artery bypass surgery; ROOBY,
Randomized On/Off Bypass.
DOI: 10.1161/JAHA.118.009934 Journal of the American Heart Association 10
Off-Pump CABG Gaudino et al
C
O
N
T
E
M
P
O
R
A
R
Y
R
E
V
IE
W
D
ow
nloaded from
 http://ahajournals.org by on November 22, 2018
No adequate RCT has compared anaortic OPCAB to
ONCAB. However, in a recent network meta-analysis compar-
ing ONCAB, OPCAB with a partial-occlusion clamp, anaortic
OPCAB, and OPCAB with a Heartstring “clampless device,” the
anaortic technique was found to result in superior short-term
outcomes. Anaortic OPCAB resulted in statistically signiﬁcant
reductions in postoperative stroke (78% versus ONCAB,
66% versus OPCAB with a partial-occlusion clamp; 52%
versus OPCAB with a Heartstring device) and early mortality
(50% versus ONCAB; 40% versus OPCAB with a Heartstring
device,20% versus OPCAB with a partial-occlusion clamp), as
well as renal failure, bleeding complications, and atrial ﬁbrilla-
tion, and shorter length of intensive care unit stay.120
The SYNTAX (Synergy between PCI with Taxus and Cardiac
Surgery) trial remains the most inﬂuential study comparing
CABG and PCI. The often quoted stroke rate of 2.2% for CABG
versus 0.6% for PCI is a signiﬁcant factor driving patients
towards PCI, despite the proven long-term survival beneﬁt and
freedom from reintervention with CABG.121 The CABG group in
this trial included both on- and off-pump patients, and the
percentage of anaortic patients is not known. Indirect
comparisons from the literature show that the anaortic
technique compares favorably with PCI (0.4% risk of stroke in
the aforementioned network meta-analysis)120 and suggests
that a formal comparative RCT would be justiﬁed.
Minimally Invasive CABG, Total Endoscopic
Coronary Artery Bypass, and HCR
The sequelae associated with the median sternotomy can
affect postoperative quality of life and recovery. It has been
estimated that more than a quarter of patients still have
chronic non-cardiac chest pain 1 year after sternotomy, and
this does not speciﬁcally relate to the harvest of the internal
thoracic artery.122 The future of surgical coronary revascular-
ization must therefore involve ways to perform effective
surgical revascularization without sternotomy.
The development of minimally invasive coronary surgical
techniques has been limited by the difﬁculty in accessing and
performing anastomosis in multiple different areas of the heart
through a single, small, nonsternotomy incision. Three main
options for the performance of CABG without sternotomy are
now available (Table 3): (1) minimally invasive CABG, in which
all areas of the heart are bypassed via a small left anterolateral
thoracotomy, usually without the use of the heart–lung
machine123; (2) robotic total endoscopic coronary bypass
grafting, in which robotic techniques are used not only for
internal mammary artery harvest but also for the performance
of all graft anastomoses124; and (3) HCR, which combines the
performance of a single LIMA-LAD graft via a small anterolateral
thoracotomy, with PCI to the other myocardial territories of the
heart that require revascularization.125
So far, observational data have suggested that these
procedures are safe and that patients recover signiﬁcantly
faster than with CABG in the early postoperative period.125–127
Furthermore, there may also be beneﬁts related to periproce-
dural morbidity compared with CABG.125
No RCT to date has compared minimally invasive
techniques with traditional CABG. Two trials are currently
under way to evaluate minimally invasive CABG and HCR:
the MIST (Minimally Invasive Coronary Surgery Compared to
Sternotomy Coronary Artery Bypass Grafting) trial and the
National Heart, Lung, and Blood Institute–funded Hybrid
Coronary Revascularization Trial. These prospective trials are
being undertaken to ascertain, respectively, the amount of
recovery beneﬁt that minimally invasive CABG may have
over sternotomy CABG and whether HCR is superior to a
strategy of multivessel PCI regarding 5-year incidence of
major adverse cardiac events. The results of these trials will
shed light on the role of nonsternotomy CABG in clinical
practice.
Conclusions
More than 30 years after the introduction of OPCAB, its role
in coronary surgery remains debated. In the general popula-
tion, OPCAB has been associated with similar short-term
outcomes, at least when performed by experienced surgeons.
In the long term, inferior outcomes have been reported with
OPCAB. High-risk patients can potentially beneﬁt from
OPCAB, and this seems to be particularly relevant for patients
at high risk of intraoperative stroke who are operated with the
anaortic technique, but this hypothesis has not been
adequately tested in randomized studies. The use of minimally
invasive and hybrid approaches is promising.
Table 3. Comparison of Nonsternotomy OPCAB Modalities
MICS CABG TECAB HCR
Safety and efficacy +++ +++ +++
Avoidance of CPB ++ + +++
Avoidance of invasiveness ++ ++ +++
Availability outside of
expert centers
+  ++
Completeness of surgical
revascularization
+++ ++ +
Ability to perform
multiarterial grafting
++ +++ 
Cost containment vs CABG +++ + ++
CABG indicates coronary artery bypass grafting; CPB, cardiopulmonary bypass; HCR,
hybrid coronary revascularization; MICS CABG, minimally invasive coronary artery bypass
grafting; OPCAB, off-pump coronary artery bypass surgery; TECAB, total endoscopic
coronary artery bypass grafting.
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